<DOC>
	<DOC>NCT00845871</DOC>
	<brief_summary>This single-arm, open-label, multi-center study will enroll 60 patients from approximately 20 centers. All patients who meet study criteria and are currently taking, beginning or resuming treatment with Deferasirox will be allowed. The study will begin with a one month run-in phase, where all patients will be instructed to take Deferasirox according to their physician's current prescribing information.</brief_summary>
	<brief_title>Palatability and Tolerability of Deferasirox Taken With Meals, With Different Liquids or Crushed and Added to Food</brief_title>
	<detailed_description>Following the run-in phase, patients will enter a three month, assessment phase. During the assessment phase, patients will have five general options for taking Deferasirox including with or without meals, crushed and added to a soft food or mixed in a liquid of choice.</detailed_description>
	<mesh_term>Hemosiderosis</mesh_term>
	<mesh_term>Deferasirox</mesh_term>
	<criteria>Male or female patients with thalassemia major, sickle cell disease (SCD), low or intermediate 1 (INT 1) risk myelodysplastic syndrome (MDS) or other anemias and transfusional hemosiderosis. Patients who were on, starting, or resuming treatment with Exjade. Patients who were &gt;2 years (i.e., 2 years of age or older). Exclusion criteria: Serum creatinine above the upper limit of normal (ULN) for age. Alanine aminotransferase (ALT) &gt;2.5 times the ULN.High risk intermediate2 or high risk MDS or acute leukemia.</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Exjade</keyword>
	<keyword>deferasirox</keyword>
	<keyword>palatability</keyword>
	<keyword>tolerability</keyword>
	<keyword>food</keyword>
	<keyword>iron overload</keyword>
	<keyword>Serum Iron overload due to transfusions</keyword>
</DOC>